tetano
Editor, Senior Moderator
J Clin Virol. 2017 Aug 9;95:1-4. doi: 10.1016/j.jcv.2017.08.002. [Epub ahead of print]
[h=1]Early estimates of 2016/17 seasonal influenza vaccine effectiveness in primary care in France.[/h] Souty C[SUP]1[/SUP], Vilcu AM[SUP]2[/SUP], Capai L[SUP]3[/SUP], van der Werf S[SUP]4[/SUP], Valette M[SUP]5[/SUP], Blanchon T[SUP]2[/SUP], Lina B[SUP]5[/SUP], Behillil S[SUP]4[/SUP], Hanslik T[SUP]6[/SUP], Falchi A[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The ongoing 2016/17 influenza epidemic in France is characterized by the circulation of A(H3N2) viruses, known to cause more severe illness among at risk populations.
[h=4]OBJECTIVES:[/h] The purpose of our study was to provide early influenza vaccine effectiveness (IVE) estimates for the ongoing influenza epidemic in France and compare these estimates over the six post-pandemic IVE.
[h=4]STUDY DESIGN:[/h] We used clinical and virological data collected in primary care by the French Sentinelles network. IVE in preventing influenza infection was estimated by the test-negative design method. The screening method was used to estimate IVE in preventing medically-attended influenza-like illness among target groups (<65year with chronic diseases and ≥65 years) since 2010/11 influenza epidemic.
[h=4]RESULTS:[/h] Early IVE estimates in primary care against influenza A(H3N2) were 48% (95% confidence interval (CI): 22-66) overall and 39% (95% CI: -17 to 69) among elderly (aged 65 and older). In comparison to the last six epidemics, 2016/17 early IVE in preventing influenza-like illness among target groups showed VE estimates higher to those reported during the 2011/12 and 2014/15 epidemics.
[h=4]CONCLUSIONS:[/h] The moderate 2016/17 IVE estimates were higher than those estimated during influenza A(H3N2) epidemics with vaccine mismatch.
Copyright ? 2017 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Influenza; Influenza-like illness; Primary care; Vaccine effectiveness
PMID: 28818690 DOI: 10.1016/j.jcv.2017.08.002
[h=1]Early estimates of 2016/17 seasonal influenza vaccine effectiveness in primary care in France.[/h] Souty C[SUP]1[/SUP], Vilcu AM[SUP]2[/SUP], Capai L[SUP]3[/SUP], van der Werf S[SUP]4[/SUP], Valette M[SUP]5[/SUP], Blanchon T[SUP]2[/SUP], Lina B[SUP]5[/SUP], Behillil S[SUP]4[/SUP], Hanslik T[SUP]6[/SUP], Falchi A[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The ongoing 2016/17 influenza epidemic in France is characterized by the circulation of A(H3N2) viruses, known to cause more severe illness among at risk populations.
[h=4]OBJECTIVES:[/h] The purpose of our study was to provide early influenza vaccine effectiveness (IVE) estimates for the ongoing influenza epidemic in France and compare these estimates over the six post-pandemic IVE.
[h=4]STUDY DESIGN:[/h] We used clinical and virological data collected in primary care by the French Sentinelles network. IVE in preventing influenza infection was estimated by the test-negative design method. The screening method was used to estimate IVE in preventing medically-attended influenza-like illness among target groups (<65year with chronic diseases and ≥65 years) since 2010/11 influenza epidemic.
[h=4]RESULTS:[/h] Early IVE estimates in primary care against influenza A(H3N2) were 48% (95% confidence interval (CI): 22-66) overall and 39% (95% CI: -17 to 69) among elderly (aged 65 and older). In comparison to the last six epidemics, 2016/17 early IVE in preventing influenza-like illness among target groups showed VE estimates higher to those reported during the 2011/12 and 2014/15 epidemics.
[h=4]CONCLUSIONS:[/h] The moderate 2016/17 IVE estimates were higher than those estimated during influenza A(H3N2) epidemics with vaccine mismatch.
Copyright ? 2017 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Influenza; Influenza-like illness; Primary care; Vaccine effectiveness
PMID: 28818690 DOI: 10.1016/j.jcv.2017.08.002